Assessment of the Effectiveness of the Metabolomic Approach in Screening for Endometrial Cancer
Launched by NATIONAL CANCER INSTITUTE, NAPLES · Mar 18, 2025
Trial Information
Current as of April 29, 2025
Recruiting
Keywords
ClinConnect Summary
This clinical trial is looking at a new way to screen for endometrial cancer, which is a type of cancer that affects the lining of the uterus. Researchers are testing a specific "metabolomic signature," a unique pattern of molecules in the body, to see if it can help tell the difference between benign (non-cancerous) growths and different types of cancerous growths. The goal is to improve early detection of endometrial carcinoma.
To participate in this study, you must be a woman aged between 50 and 80 who is post-menopausal and willing to sign consent to take part. Unfortunately, if you've had a hysterectomy, are on hormone replacement therapy, or are receiving immunosuppressive treatment, you would not be eligible. If you join the trial, you’ll help researchers learn more about this potential new screening method, which could ultimately lead to better outcomes for women facing this cancer.
Gender
FEMALE
Eligibility criteria
- Inclusion Criteria:
- • 1. Female sex
- • 2. Age between 50 and 80 years
- • 3. Willingness to participate in the study and signing of the informed consent
- • 4. Clinical condition of post-menopause
- Exclusion Criteria:
- • 1. Previous hysterectomy
- • 2. Hormone replacement therapy
- • 3. Immunosuppressive therapy
About National Cancer Institute, Naples
The National Cancer Institute (NCI) in Naples is a leading research institution dedicated to advancing the understanding and treatment of cancer through innovative clinical trials. As a prominent sponsor of cancer research, the NCI focuses on developing novel therapies, improving patient outcomes, and exploring cutting-edge methodologies in oncology. With a commitment to scientific rigor and collaboration, the NCI in Naples engages in partnerships with academic institutions and healthcare providers to facilitate groundbreaking studies that address critical challenges in cancer care. Their mission is to translate research findings into effective treatments, ultimately enhancing the lives of patients affected by cancer.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Napoli, , Italy
Patients applied
Trial Officials
Antonella De Luca
Principal Investigator
IRCCS I.N.T. "G. Pascale"
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported